Trastuzumab Deruxtecan + Neratinib for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine the safest and most effective dose of a drug combination for treating certain difficult-to-treat cancers. It focuses on using two drugs, neratinib (neratinib maleate) and trastuzumab deruxtecan (also known as Enhertu or DS-8201a), to target cancers with changes in the HER2 gene. The goal is to assess whether these drugs can shrink tumors that have spread or cannot be surgically removed. Individuals with HER2-altered cancer who have undergone at least one prior treatment may be suitable candidates for this trial. As a Phase 1 trial, the research seeks to understand how the treatment works in people, offering participants a chance to contribute to groundbreaking cancer research.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, certain medications, especially those that are moderate or strong inhibitors or inducers of CYP3A4 and P-glycoprotein, are not allowed. It's important to discuss your current medications with the study team to ensure there are no interactions.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that the combination of the drugs neratinib and trastuzumab deruxtecan is under study to assess its safety and possible side effects. Previous studies have found that using these two drugs together can more effectively block HER2, a protein that can promote cancer cell growth. Although this combination remains under investigation, early results have noted common side effects such as diarrhea, nausea, and tiredness. These side effects are typical for cancer treatments and can usually be managed with supportive care.
The safety of trastuzumab deruxtecan alone was reviewed in 645 patients with different types of tumors, demonstrating a known safety record. However, since this trial is in its early stages, it primarily focuses on how well participants can tolerate these two drugs together. The trial will carefully monitor for any unexpected side effects.
Participants in the trial will have their health closely monitored by medical staff to manage any side effects that may occur.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of Trastuzumab Deruxtecan and Neratinib because these treatments offer a new approach to targeting cancer cells. Trastuzumab Deruxtecan is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells, potentially minimizing damage to healthy cells, unlike traditional chemotherapy that affects both. Neratinib, on the other hand, is a tyrosine kinase inhibitor that blocks signals that help cancer cells grow. Together, they form a one-two punch that could be more effective than current treatments like Herceptin and other HER2-targeting therapies, by potentially overcoming resistance and offering more precise, potent cancer cell targeting.
What evidence suggests that this trial's treatments could be effective for metastatic or unresectable solid tumors with HER2 gene changes?
Research has shown that using neratinib with trastuzumab deruxtecan might help treat certain HER2-positive cancers. In this trial, participants will receive a combination of these two treatments. Neratinib blocks a protein that signals cancer cells to grow, potentially stopping or slowing the cancer. Trastuzumab deruxtecan targets HER2-positive cancer cells and delivers chemotherapy directly to them. Early findings suggest that this combination could effectively shrink tumors with HER2 changes. Initial studies have shown promise, particularly in breast cancers with low HER2 levels.12467
Who Is on the Research Team?
Andrew A Davis
Principal Investigator
Yale University Cancer Center LAO
Are You a Good Fit for This Trial?
Adults with advanced solid tumors that can't be removed by surgery or have spread, and have changes in the HER2 gene. They must not have had previous treatments with neratinib or DS-8201a, should not be pregnant or breastfeeding, and need to agree to use contraception. People with certain heart conditions, severe lung issues, recent major surgeries or radiation therapy are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Patients receive neratinib and trastuzumab deruxtecan to assess dose limiting toxicities and determine the maximum tolerated dose
Dose Expansion
Patients continue to receive neratinib and trastuzumab deruxtecan at the recommended phase 2 dose to observe anti-tumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Neratinib Maleate
- Trastuzumab Deruxtecan
Trial Overview
The trial is testing the combination of two anti-cancer drugs: Trastuzumab Deruxtecan and Neratinib Maleate for safety and optimal dosing against cancers with HER2 gene alterations. It includes various assessments like scans and biopsies to monitor effects.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients receive neratinib PO QD on days 1-21 (days 8-21 of cycle 1, then days 1-21 in cycles thereafter for PD study) of each cycle and trastuzumab deruxtecan IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT scan and echocardiography or MUGA scan throughout study. Additionally, patients may undergo a tissue biopsy at baseline and disease progression.
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
Citations
Neratinib could be effective as monotherapy or in combination ...
This study demonstrates that neratinib in combination with trastuzumab may be effective in a subset of HER2-low breast cancers.
2.
aacrjournals.org
aacrjournals.org/cancerres/article/85/8_Supplement_2/CT071/761598/Abstract-CT071-Phase-I-trial-of-trastuzumabAbstract CT071: Phase I trial of trastuzumab deruxtecan in ...
This is a multi-center, phase I clinical trial (NCT05372614) with a 3+3 design to evaluate the safety and tolerability of T-DXd in combination with neratinib.
Testing the Safety and Tolerability of the Anti-cancer Drugs ...
An unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain amount of ...
Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in ...
This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors.
5.
onclive.com
onclive.com/view/dr-davis-on-the-investigation-of-neratinib-plus-trastuzumab-deruxtecan-in-advanced-her2-solid-tumorsDr Davis on the Investigation of Neratinib Plus ... - OncLive
Andrew Davis, MD, discusses an ongoing phase 1 trial combining neratinib and trastuzumab deruxtecan in metastatic HER2-positive solid tumors.
KCSG AL20‐17/KM23 trial
Preclinical and clinical studies demonstrate that combining neratinib with trastuzumab enhances HER2 signaling inhibition and improves outcomes in HER2‐mutated ...
Multi-Discipline Review - accessdata.fda.gov
Review of Safety. Data: The safety profile of fam-trastuzumab deruxtecan is based on data from 645 subjects with various tumor types treated ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.